US7709454B2
(en)
*
|
1997-06-20 |
2010-05-04 |
New York University |
Methods and compositions for inhibiting tumorigenesis
|
US7741298B2
(en)
*
|
1997-06-20 |
2010-06-22 |
New York University |
Method and compositions for inhibiting tumorigenesis
|
US7230000B1
(en)
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
US7671200B2
(en)
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
DK1730280T3
(en)
|
2004-03-26 |
2019-02-04 |
Curis Inc |
RNA interference modulators for hedgehog signaling and applications thereof
|
JPWO2006101273A1
(en)
*
|
2005-03-25 |
2008-09-04 |
武田薬品工業株式会社 |
Cancer preventive / therapeutic agent
|
AU2006332945C1
(en)
|
2005-12-23 |
2013-02-28 |
Wyeth |
Modified lysine-mimetic compounds
|
EP2074087A2
(en)
|
2006-12-21 |
2009-07-01 |
Wyeth |
Synthesis of pyrrolidine compounds
|
TWI433674B
(en)
|
2006-12-28 |
2014-04-11 |
Infinity Discovery Inc |
Cyclopamine analogs
|
AU2008345097A1
(en)
|
2007-12-27 |
2009-07-09 |
Infinity Pharmaceuticals, Inc. |
Methods for stereoselective reduction
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
GEP20125664B
(en)
|
2008-02-26 |
2012-10-10 |
Takeda Pharmaceuticals Co |
Condensed heterocyclic derivatives and application thereof
|
US20110217294A1
(en)
*
|
2008-04-11 |
2011-09-08 |
Daniel Fults |
Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
|
BRPI0911618A2
(en)
|
2008-04-29 |
2019-09-24 |
Lilly Co Eli |
disrupted phthalazine hedgehog pathway antagonists.
|
EA018931B1
(en)
|
2008-11-03 |
2013-11-29 |
Эли Лилли Энд Компани |
Disubstituted phthalazine hedgehog pathway antagonists
|
KR101335770B1
(en)
|
2008-11-17 |
2013-12-12 |
일라이 릴리 앤드 캄파니 |
Tetrasubstituted pyridazines hedgehog pathway antagonists
|
CN102216285B
(en)
|
2008-11-17 |
2014-08-13 |
伊莱利利公司 |
Tetrasubstituted pyridazine hedgehog pathway antagonists
|
AR077014A1
(en)
|
2009-06-19 |
2011-07-27 |
Lilly Co Eli |
COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER
|
CA2769795C
(en)
|
2009-08-05 |
2020-01-07 |
Infinity Pharmaceuticals, Inc. |
Enzymatic transamination of cyclopamine analogs
|
US8614208B2
(en)
|
2009-08-26 |
2013-12-24 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic ring derivative and use thereof
|
WO2011024869A1
(en)
|
2009-08-26 |
2011-03-03 |
武田薬品工業株式会社 |
Fused heterocyclic ring derivative and use thereof
|
JP5599802B2
(en)
|
2009-08-26 |
2014-10-01 |
武田薬品工業株式会社 |
Fused heterocyclic derivatives and uses thereof
|
US8927718B2
(en)
|
2009-08-26 |
2015-01-06 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic ring derivative and use thereof
|
ES2593256T3
(en)
|
2010-05-21 |
2016-12-07 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulations
|
WO2012037217A1
(en)
|
2010-09-14 |
2012-03-22 |
Infinity Pharmaceuticals, Inc. |
Transfer hydrogenation of cyclopamine analogs
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN103648499B
(en)
|
2011-01-10 |
2017-02-15 |
无限药品股份有限公司 |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
EP2734520B1
(en)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013032591A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
ES2691742T5
(en)
|
2012-11-01 |
2022-03-18 |
Infinity Pharmaceuticals Inc |
Treatment of Cancers Using Modulators of PI3 Kinase Isoforms
|
AU2013352256A1
(en)
|
2012-11-29 |
2015-06-18 |
Strasspharma, Llc |
Methods of modulating follicle stimulating hormone activity
|
JP6806562B2
(en)
|
2013-03-15 |
2021-01-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Regulator of the eIF2α pathway
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
US20160113932A1
(en)
|
2013-05-30 |
2016-04-28 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
CA2925944C
(en)
|
2013-10-04 |
2023-01-10 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN104906113A
(en)
*
|
2014-03-12 |
2015-09-16 |
淄博赛维医药技术有限公司 |
Antitumor medicine
|
EP4066834A1
(en)
|
2014-03-19 |
2022-10-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
US20150320754A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
MX2017015681A
(en)
|
2015-06-04 |
2018-09-11 |
Pellepharm Inc |
Topical formulations for delivery of hedgehog inhibitor compounds and use thereof.
|
WO2017139497A1
(en)
|
2016-02-11 |
2017-08-17 |
PellePharm, Inc. |
Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2017223422A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
DK3618847T3
(en)
|
2017-05-05 |
2021-05-25 |
Boston Medical Ct Corp |
GAP junction modulators of intercellular communication and their use in the treatment of diabetic eye disease
|